Bendamustine appears to be a safe and effective alternative to carmustine when combined with etoposide, cytarabine and melphalan as conditioning regimen for autologous HCT for lymphomas: results of a systematic review/meta-analysis.

MLA

Rafei, Hind, et al. “Bendamustine Appears to Be a Safe and Effective Alternative to Carmustine When Combined with Etoposide, Cytarabine and Melphalan as Conditioning Regimen for Autologous HCT for Lymphomas: Results of a Systematic Review/Meta-Analysis.” Clinical Lymphoma, Myeloma & Leukemia, vol. 17, Sept. 2017, p. S361. EBSCOhost, https://doi.org/10.1016/j.clml.2017.07.194.

APA

Rafei, H., Reljic, T., Nishihori, T., Ayala, E., Kumar, A., & Kharfan-Dabaja, M. A. (2017). Bendamustine appears to be a safe and effective alternative to carmustine when combined with etoposide, cytarabine and melphalan as conditioning regimen for autologous HCT for lymphomas: results of a systematic review/meta-analysis. Clinical Lymphoma, Myeloma & Leukemia, 17, S361. https://doi.org/10.1016/j.clml.2017.07.194

Chicago

Rafei, Hind, Tea Reljic, Taiga Nishihori, Ernesto Ayala, Ambuj Kumar, and Mohamed A. Kharfan-Dabaja. 2017. “Bendamustine Appears to Be a Safe and Effective Alternative to Carmustine When Combined with Etoposide, Cytarabine and Melphalan as Conditioning Regimen for Autologous HCT for Lymphomas: Results of a Systematic Review/Meta-Analysis.” Clinical Lymphoma, Myeloma & Leukemia 17 (September): S361. doi:10.1016/j.clml.2017.07.194.